The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human
Robin McDougall(AEgis Technologies (United States)), Jing‐Tao Wu(Aviation Industry Corporation of China (China)), Jayaprakash K. Nair(Alnylam Pharmaceuticals (United States)), Maja M. Janas(Alnylam Pharmaceuticals (United States)), Scott Waldron(Alnylam Pharmaceuticals (United States)), Pete Smith(University of Aberdeen), Steven Liou(Alnylam Pharmaceuticals (United States)), Jeffrey C. Kurz(Alnylam Pharmaceuticals (United States)), Vasant Jadhav(Alnylam Pharmaceuticals (United States)), Chris Maclauchlin(Alnylam Pharmaceuticals (United States)), Yuanxin Xu(Nanjing University of Chinese Medicine), Muthusamy Jayaraman(Forma Therapeutics (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States)), Xiumin Liu(Alnylam Pharmaceuticals (United States)), Christopher R. Brown(Alnylam Pharmaceuticals (United States)), Saket Agarwal(Alnylam Pharmaceuticals (United States)), Christopher S. Theile(Alnylam Pharmaceuticals (United States)), Krishna Aluri(Alnylam Pharmaceuticals (United States)), Akshay Vaishnaw(Alnylam Pharmaceuticals (United States)), Ivan Zlatev(Alnylam Pharmaceuticals (United States)), Varun Goel(Alnylam Pharmaceuticals (United States)), Gabriel J. Robbie(Alnylam Pharmaceuticals (United States)), Sagar Agarwal(Alnylam Pharmaceuticals (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Karyn Schmidt(Alnylam Pharmaceuticals (United States)), Bahru Habtemariam(Center for Drug Evaluation and Research), Joseph A. Cichocki(Alnylam Pharmaceuticals (United States)), Jing Li(Jinan University), Xuemei Zhang(Weifang Medical University), Ju Liu(Liaoning University), Diane Ramsden(Alnylam Pharmaceuticals (United States)), Saeho Chong(Alnylam Pharmaceuticals (United States)), Yongli Gu(Alnylam Pharmaceuticals (United States)), Kevin Fitzgerald(Epsilon Systems (United States)), Dale C. Guenther(University of Idaho), Michael Arciprete(Alnylam Pharmaceuticals (United States)), Klaus Charissé(Alnylam Pharmaceuticals (United States)), Elena Castellanos-Rizaldos(Alnylam Pharmaceuticals (United States))
Cited by 106
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
Ecosystem Service Supply and Vulnerability to Global Change in Europe
|Science|2005|1.7k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Biophysical and economic limits to negative CO2 emissions
|Nature Climate Change|2015|1.5k